Clinical Trial Update: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of patidegib gel 2% for preventing basal cell carcinomas on the face in adults with Gorlin syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Gorlin Syndrome

Drugs mentioned

• Patidegib Gel 2% (patidegib)

Snippet

Sponsor: Sol-Gel Technologies, Ltd. | Conditions: Gorlin Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING